Don’t let the high cost of brand specialty resistant Pseudomonas/gram-negative therapy disrupt your treatment. We help eligible patients access Zerbaxa (ceftolozane/tazobactam) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
Zerbaxa PAP for MDR gram-negative infections.
Eligibility, ID/hospital coordination.
AffordMyPrescriptions eliminates that burden. $69.95/month advocacy.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Hospital pharmacy | ~$650/dose | Save substantially |
| Inpatient billing | ~$700/dose | Save substantially |
| Specialty Pharmacy | ~$500/dose | Save substantially |
| Specialty Pharmacy | ~$420/dose | Save substantially |
Costco | ~$410/dose | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
PAP at no cost. Typically inpatient — hospital billing coordination important.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Zerbaxa:
Still $400–$700 per dose per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Zerbaxa assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Zerbaxa combines ceftolozane (a novel cephalosporin with enhanced activity against Pseudomonas aeruginosa) and tazobactam (β-lactamase inhibitor). Particularly useful for drug-resistant Pseudomonas infections — including multidrug-resistant strains with AmpC overexpression or efflux mechanisms.
How Zerbaxa Works:
Pseudomonas aeruginosa has multiple resistance mechanisms — chromosomal AmpC β-lactamase, efflux pumps, porin loss, target modification. Multi-drug-resistant Pseudomonas is a major nosocomial pathogen with limited options.
Ceftolozane is structurally similar to ceftazidime but with enhanced affinity for Pseudomonas PBP3 and resistance to AmpC β-lactamase activity. Tazobactam inhibits ESBL β-lactamases. The combination has improved activity against MDR Pseudomonas vs. traditional anti-pseudomonal β-lactams. Not active against carbapenem-resistant Enterobacterales with KPC carbapenemases (use Avycaz, Recarbrio, or Vabomere for those).
Form and use:
Zerbaxa given as IV infusion over 1 hour every 8 hours. Higher dose (3 g — 2 g ceftolozane / 1 g tazobactam) for HABP/VABP; standard dose (1.5 g — 1 g/0.5 g) for cUTI/cIAI. Renal dose adjustment for CrCl <50.
Generic availability:
No generic. Other agents for MDR Pseudomonas: traditional anti-pseudomonal β-lactams (cefepime, piperacillin/tazobactam, meropenem, imipenem — if susceptible), aminoglycosides (gentamicin, tobramycin, amikacin), fluoroquinolones (ciprofloxacin, levofloxacin — if susceptible), polymyxins (colistin, polymyxin B). For carbapenem-resistant strains: Avycaz, Recarbrio, Vabomere, Fetroja depending on resistance mechanism.
Warnings:
Zerbaxa carries warnings for hypersensitivity reactions (severe, including anaphylaxis — caution in β-lactam allergy), reduced clinical response in patients with renal impairment (creatinine clearance changes during therapy), C. difficile diarrhea, drug-resistant bacteria emergence with inappropriate use.
$400–$700/dose. Course $8,000–$20,000+. Hospital billing typically includes.
Drug-resistant gram-negative infections — especially MDR Pseudomonas aeruginosa. Inpatient use coordinated by ID specialist with culture/susceptibility data. Not for CRE (use Avycaz/Recarbrio/Vabomere). Not first-line for susceptible infections (use older β-lactams).
Pseudomonas with multiple resistance mechanisms — common in ICU, immunocompromised, prolonged hospitalization, prior antibiotic exposure. Zerbaxa often the agent of choice when standard anti-pseudomonal β-lactams fail. ID consultation essential.
Zerbaxa NOT active against most carbapenem-resistant Enterobacterales (KPC, OXA-48, metallo-β-lactamases). Use Avycaz (KPC, OXA-48), Recarbrio (KPC), Vabomere (KPC), or Fetroja (broad including metallo-β-lactamases) based on resistance pattern.
Caution in severe β-lactam allergy. ID team assesses risk vs. need; allergy testing may be considered.
Important — renal function changes during therapy (especially in critically ill patients). Frequent reassessment and dose adjustment needed.
ID consult to assess alternatives. Hospital charity programs. PAP if uninsured.
If facing Zerbaxa cost, we can help coordinate manufacturer PAP and hospital billing. Check eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.